Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Zuranolone

FDA-approved product (capsule, oral), marketed as Zurzuvae.

Registered studies
17
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Zuranolone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Depressive disorder
  • Major depressive disorder
  • Postpartum depression

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antidepressants
FDA pharmacologic class
Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

17registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Zuranolone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Zuranolone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

    NCT03000530 · start 2016-12-07

    Registered record
    Registry ID
    NCT03000530
    Conditions
    Major Depression
    Interventions
    SAGE-217; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-12-07
    Completion
    2017-11-08
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depression
    InterventionSAGE-217; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

    NCT03000569 · start 2016-11-30

    Registered record
    Registry ID
    NCT03000569
    Conditions
    Parkinson Disease
    Interventions
    SAGE-217; Levodopa; Antiparkinsonian Agent(s)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-11-30
    Completion
    2017-09-11
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionSAGE-217; Levodopa; Antiparkinsonian Agent(s)
    PhasePhase 2
    Registry statusCompleted